Log Out

GSK (GSK) Scheduled to Post Quarterly Earnings on Wednesday

Defense World · Jan 25, 2023 02:11

GSK (NYSE:GSK – Get Rating) is set to post its quarterly earnings results before the market opens on Wednesday, February 1st. Analysts expect GSK to post earnings of $0.59 per share for the quarter. GSK has set its FY 2022 guidance at EPS.Persons that are interested in registering for the company's earnings conference call can do so using this link.

GSK (NYSE:GSK – Get Rating) last released its quarterly earnings data on Wednesday, November 2nd. The pharmaceutical company reported $1.09 earnings per share for the quarter, beating the consensus estimate of $0.90 by $0.19. The company had revenue of $9.22 billion during the quarter, compared to analyst estimates of $7.75 billion. GSK had a net margin of 37.88% and a return on equity of 32.18%. On average, analysts expect GSK to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Get GSK alerts:

GSK Stock Down 1.9 %

Shares of NYSE GSK opened at $34.70 on Wednesday. The company has a quick ratio of 0.74, a current ratio of 0.97 and a debt-to-equity ratio of 2.22. The firm has a market cap of $71.03 billion, a PE ratio of 4.25, a P/E/G ratio of 1.19 and a beta of 0.66. The company's fifty day simple moving average is $34.97 and its 200 day simple moving average is $34.54. GSK has a 12-month low of $28.47 and a 12-month high of $46.97.

GSK Cuts Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, January 12th. Stockholders of record on Friday, November 18th were issued a dividend of $0.3695 per share. The ex-dividend date was Thursday, November 17th. This represents a $1.48 annualized dividend and a dividend yield of 4.26%. GSK's dividend payout ratio is currently 16.05%.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Barclays decreased their target price on GSK from GBX 1,800 ($22.29) to GBX 1,450 ($17.95) in a research report on Friday, October 14th. UBS Group lowered GSK from a "neutral" rating to a "sell" rating in a research report on Friday, November 11th. StockNews.com cut GSK from a "strong-buy" rating to a "buy" rating in a report on Wednesday, January 18th. AlphaValue raised shares of GSK to a "buy" rating in a research report on Thursday, December 8th. Finally, Bank of America lowered GSK from a "neutral" rating to an "underperform" rating in a research report on Monday, December 5th. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $1,583.57.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Nelson Van Denburg & Campbell Wealth Management Group LLC boosted its position in shares of GSK by 61.3% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 968 shares of the pharmaceutical company's stock valued at $42,000 after acquiring an additional 368 shares during the period. Fairfield Bush & CO. bought a new position in GSK in the 1st quarter valued at $80,000. Merit Financial Group LLC purchased a new position in shares of GSK during the 1st quarter valued at $238,000. Enlightenment Research LLC bought a new position in shares of GSK in the first quarter worth $244,000. Finally, Invesco Ltd. raised its position in shares of GSK by 6.9% in the first quarter. Invesco Ltd. now owns 6,418 shares of the pharmaceutical company's stock worth $280,000 after buying an additional 414 shares in the last quarter. Hedge funds and other institutional investors own 13.15% of the company's stock.

About GSK

(Get Rating)

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation.